FDA 483 - MSD Ireland (Carlow)

MSD International GmbH T/A MSD Ireland (Carlow) received three observations during an FDA inspection. The observations highlight deficiencies in aseptic processing controls, specifically regarding first air operations and smoke studies for a vial filling line. Additionally, the firm's visual inspection process for drug product was found to lack adequate process controls for rejected vials.